Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: Role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways

Journal of Neuroscience

Volumn 35, Issue 14, 2015, Pages 5781-5791

  Padovan Neto, Fernando E ^a   Sammut, Stephen ^a,c   Chakroborty, Shreaya ^a   Dec, Alexander M ^a   Threlfell, Sarah ^a,d   Campbell, Peter W ^a   Mudrakola, Vishnu ^a   Harms, John F ^b   Schmidt, Christopher J ^b   West, Anthony R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c FRANCISCAN UNIVERSITY OF STEUBENVILLE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cGMP; Medium sized spiny neuron; Nitric oxide; Nitric oxide synthase; Phosphodiesterase 10A; Soluble guanylyl cyclase

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NEURONAL NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CORPUS STRIATUM; CORTICOSTRIATAL TRANSMISSION; ENZYME INHIBITION; MALE; MOUSE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; ACTION POTENTIAL; ANIMAL; BIOPHYSICS; BRAIN CORTEX; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; ELECTROSTIMULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MICRODIALYSIS; NERVE CELL; NERVE TRACT; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ACTION POTENTIALS; ANIMALS; BIOPHYSICS; CEREBRAL CORTEX; CORPUS STRIATUM; CYCLIC AMP; CYCLIC GMP; ELECTRIC STIMULATION; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; NEURAL PATHWAYS; NEURONS; NITRIC OXIDE SYNTHASE TYPE I; PHOSPHORIC DIESTER HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84929340487     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1238-14.2015     Document Type: Article

References (56)

1. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520.
2. Calabresi P, Di Filippo M, Gallina A, Wang Y, Stankowski JN, Picconi B, Dawson VL, Dawson TM (2013) New synaptic and molecular targets for neuroprotection in Parkinson’s disease. Mov Disord 28:51–60.
3. Cechova S, Pajewski TN (2004) The soluble guanylyl cyclase inhibitor ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, dose-dependently reduces the threshold for isoflurane anesthesia in rats. Anesth Analg 99: 752–757.
4. Colwell CS, Levine MS (1995) Excitatory synaptic transmission in neostriatal neurons: regulation by cyclic AMP-dependent mechanisms. J Neurosci 15:1704–1713.
5. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481–511.
6. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54:1205–1213.
7. Cramer H, Warter JM, Renaud B (1984) Analysis of neurotransmitter metabolites and adenosine 3,5-monophosphate in the CSF of patients with extrapyramidal motor disorders. Adv Neurol 40:431–435.
8. Deckel AW (2001) Nitric oxide and nitric oxide synthase in Huntington’s disease. J Neurosci Res 64:99–107.
9. Fujishige K, Kotera J, Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266:1118–1127.
10. Fujishige K, Kotera J, Yuasa K, Omori K (2000) The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 267:5943– 5951.
11. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B (1995) Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48:184–188.
12. Giampà C, Patassini S, Borreca A, Laurenti D, Marullo F, Bernardi G, Menniti FS, Fusco FR (2009) Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington’s disease. Neurobiol Dis 34:450–456.
13. Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington’s disease. PLoS One 5:e13417.
14. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet 12:497–508.
15. Giorgi M, D’Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G (2008) Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28:941–950.
16. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574– 590.
17. Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294:1024–1030.
18. Hebb AL, Robertson HA (2007) Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 7:86–92.
19. Hofer AM, Lefkimmiatis K (2007) Extracellular calcium and cAMP: second messengers as “third messengers?” Physiology (Bethesda) 22:320–327.
20. Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ (2011) Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington’s disease. J Pharmacol Exp Ther 336: 64–76.
21. Kostowski W, Gajewska S, Bidzinski A, Hauptman M (1976) Papaverine, drug-induced stereotypy and catalepsy and biogenic amines in the brain of the rat. Pharmacol Biochem Behav 5:15–17.
22. Kraus MM, Prast H, Philippu A (2014) Influence of parafascicular thalamic input on neuronal activity within the nucleus accumbens is mediated by nitric oxide: an in vivo study. Life Sci 102:49–54.
23. Liu CN, Liu X, Gao D, Li S (2005) Effects of SNP, GLU and GABA on the neuronal activity of striatum nucleus in rats. Pharmacol Res 51:547–551.
24. Logrip ML, Zorrilla EP (2012) Stress history increases alcohol intake in relapse: relation to phosphodiesterase 10A. Addict Biol 17:920–933.
25. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3, 5-cyclic nucleotide phosphodiesterase. Gene 234:109–117.
26. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366–398.
27. Mallet N, Le Moine C, Charpier S, Gonon F (2005) Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo. J Neurosci 25:3857–3869.
28. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670.
29. Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P (2005) Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 102:1199–1204.
30. Norris PJ, Faull RL, Emson PC (1996) Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer’s disease brains. Brain Res Mol Brain Res 41:36–49.
31. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309–327.
32. Ondracek JM, Dec A, Hoque KE, Lim SA, Rasouli G, Indorkar RP, Linardakis J, Klika B, Mukherji SJ, Burnazi M, Threlfell S, Sammut S, West AR (2008) Feed-forward excitation of striatal neuron activity by frontal cortical activation of nitric oxide signaling in vivo. Eur J Neurosci 27:1739– 1754.
33. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. San Diego: Academic.
34. Paxinos G, Franklin, KBJ (2012) The mouse brain in stereotaxic coordinates. San Diego: Academic.
35. Pérez-Severiano F, Escalante B, Vergara P, Ríos C, Segovia J (2002) Agedependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation. Brain Res 951:36–42.
36. Picconi B, Bagetta V, Ghiglieri V, Paillè V, Di Filippo M, Pendolino V, Tozzi A, Giampà C, Fusco FR, Sgobio C, Calabresi P (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134:375–387.
37. Sammut S, Threlfell S, West AR (2010) Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo. Neuropharmacology 58:624–631.
38. Sancesario G, Giorgi M, D’Angelo V, Modica A, Martorana A, Morello M, Bengtson CP, Bernardi G (2004) Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci 20:989–1000.
39. Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuronspecific phosphodiesterase 10A2. J Neurochem 105:546–556.
40. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681–690.
41. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113–126.
42. Sharott A, Doig NM, Mallet N, Magill PJ (2012) Relationships between the firing of identified striatal interneurons and spontaneous and driven cortical activities in vivo. J Neurosci 32:13221–13236.
43. Shepherd GM (2013) Corticostriatal connectivity and its role in disease. Nat Rev Neurosci 14:278–291.
44. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ (2006a) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386–396.
45. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ (2006b) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374–385.
46. Soderling SH, Bayuga SJ, Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A 96:7071–7076.
47. Threlfell S, West AR (2013) Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition. Basal Ganglia 3:137–146.
48. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328:785–795.
49. Tseng KY, Snyder-Keller A, O’Donnell P (2007) Dopaminergic modulation of striatal plateau depolarizations in corticostriatal organotypic cocultures. Psychopharmacology (Berl) 191:627–640.
50. Tseng KY, Caballero A, Dec A, Cass DK, Simak N, Sunu E, Park MJ, Blume SR, Sammut S, Park DJ, West AR (2011) Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism. PLoS One 6:e27187.
51. West AR (2010) Nitric oxide signaling in the striatum. In: Handbook of basal ganglia structure and function. San Diego: Academic/Elsevier.
52. West AR, Galloway MP (1997) Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms. Neuropharmacology 36:1571–1581.
53. West AR, Grace AA (2004) The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo. J Neurosci 24: 1924–1935.
54. West AR, Tseng KY (2011) Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson’s disease? Front Syst Neurosci 5:55.
55. West AR, Galloway MP, Grace AA (2002) Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44:227–245.
56. Xie M, Rich TC, Scheitrum C, Conti M, Richter W (2011) Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP. Mol Pharmacol 80:281–293.